The role of the renin-angiotensin system in cholesterol and puromycin mediated renal injury

American Journal of the Medical Sciences

Volumn 324, Issue 6, 2002, Pages 296-304

  Ghosh, Siddhartha ^a   Sica, Domenic A ^a   Schoolwerth, Anton C ^a   Quigg, Richard J ^b   Haas, Mark ^c   Fakhry, Itaf ^a   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin; AT1 receptor; AT2 receptor; Cholesterol; Renal injury

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; PUROMYCIN; PUROMYCIN AMINONUCLEOSIDE; RENIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME ACTIVITY; GLOMERULOSCLEROSIS; KIDNEY DISEASE; KIDNEY INJURY; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RAT; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036948840     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200212000-00002     Document Type: Article

References (38)

1. Glasser RJ, Velosa JA, Michael AF. Experimental model of focal sclerosis. I Relationship to protein excretion in aminonucleoside nephrosis. Lab Invest 1977;36:519-26.
2. Chandra M, Susin M, Teichberg S, et al. Experimental focal segmental glomerulosclerosis: correlation with protein excretion, glomerular filtration rate, and renal plasma flow. Pediatr Res 1984;18:1195-201.
3. Grond J, Weening JJ, Elemma JD. Glomerular sclerosis in nephrotic rats: comparison of the long-term effects of adriamycin and aminonucleoside. Lab Invest 1984; 51:277-84.
4. Trachtman H, Schwob N, Maesaka J, et al. Dietary vitamin E supplementation ameliorates renal injury in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 1995;5:1811-9.
5. Olson JL, Hostetter TH, Rennke HG, et al. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int 1982;22:112-26.
6. Kashgarian M. Mesangium and glomerular disease. Lab Invest 1985;52:569-71.
7. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307: 652-9.
8. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-93.
9. Kiprov DD, Colvin RB, McCluskey RT. Focal and segmental glomerulosclerosis and proteinuria associated with unilateral renal agenesis. Lab Invest 1982;46:275-81.
10. Couser WG, Stilmant MM. Mesangial lesions and focal glomerular sclerosis in the aging rat. Lab Invest 1975;33: 491-501.
11. Kreisberg JI, Karnovsky MJ. Focal glomerular sclerosis in the fawn-hooded rat. Amer J Pathol 1978;92:637-52.
12. Fogo A, Yoshida Y, Glick AD, et al. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988;82:456-61.
13. Diamond JR, Karnovsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987;32:671-7.
14. Yoshida Y, Fogo A, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 1989;35:654-60.
15. Diamond JR, Anderson S. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 1990;137:1323-32.
16. Homma T, Akai Y, Burns KD, et al. Activation of S6 kinase activity by repeated cycles of stretching and relaxation in cultured rat glomerular mesangial cells. Evidence for involvement of protein kinase C. J Biol Chem 1992;267:23129-35.
17. 1 receptors. Kidney Int 1994;45:177-84.
18. Schunkert H, Ingelfinger JR, Hirsch AT, et al. Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. Circ Res 1993;72:312-8.
19. Fox J, Guan S, Hymel AA, et al. Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol 1992;262:F902-9.
20. Abboud HE. Role of platelet-derived growth factor in renal injury. Annu Rev Physiol 1995;57:297-309.
21. Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
22. Stoll M, Meffert S, Stroth U, et al. Growth or antigrowth: angiotensin and the endothelium. J Hypertens 1995;13:1529-33.
23. Keane WF. Lipids and progressive renal failure. Wien Klin Wochenschr 1996;108:420-4.
24. Wagner J, Gehlen F, Ciechanowicz A, et al. Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 1999;10: 545-51.
25. Levy BI, Benessiano J, Henrion D, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996;98: 418-25.
26. Stoll M, Steckelings UM, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-57.
27. Goto M, Mukoyama M, Suga S, et al. Growth-dependent induction of angiotensin II type 2 receptor in rat mesangial cells. Hypertension 1997;30:358-62.
28. Dudley DT, Summerfelt RM. Regulated expression of angiotensin II (AT2) binding sites in R3T3 cells. Regul Pept 1993;44:199-206.
29. 2 receptor degradation is prevented by ligand occupation. Biochem Biophys Res Commun 1998;243: 142-147
30. Tsutsumi Y, Matsubara H, Ohkubo N, et al. Angiotensin II type 2 receptor is upregulated in human hearts with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998;83:1035-46.
31. Shibata K, Makino I, Shibaguchi H, et al. Up-regulation of angiotensin type 2 receptor mRNA by angiotensin II in rat cortical cells. Biochem Biophys Res Commun 1997; 239:633-7.
32. 2 receptors in the rat skin during experimental wound healing. Peptides 1992;13:783-6.
33. Vaziri ND, Liang K. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 2002;61:1769-75.
34. Diamond JR. Role of cholesterol in glomerular injury. In: Keane WF, Stein JH, editors. Lipids and renal disease. New York: Churchill Livingstone; 1991. p. 109-26.
35. Song K, Shiota N, Takai S, et al. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys. Atherosclerosis 1998;138:171-82.
36. Wintroub BU, Klickstein LB, Dzau VJ, et al. Granulocyte-angiotensin system. Identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. Biochemistry 1984;23:227-32.
37. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.
38. Arevalo AE, Ibarra-Rubio ME, Cruz C, et al. Angiotensin-I converting enzyme activity in puromycin aminonucleoside-nephrotic syndrome. Clin Chim Acta 1990;191:175-84.